RLYB shares surge 10.46% premarket after receiving $12.5M equity milestone payment from Recursion for REV102 program advancement.

Rallybio Corporation (RLYB) surged 10.46% in premarket trading following the completion of dosing in the first cohort of its RLYB116 Phase 1 pharmacokinetic/pharmacodynamic study, a key development for its pipeline advancement. Additionally, the company had previously received a $12.5 million equity milestone payment from Recursion Pharmaceuticals for the advancement of the REV102 program, which may have bolstered investor confidence. These updates, highlighting progress in clinical trials and secured funding, align with the stock’s upward movement, signaling optimism around therapeutic development and partnership milestones.